Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL8425141 | 0.97 | TDP1 (0.33) | TDP1PTGS1AKR1C3CYP2C9PARP1 | |
| SCHEMBL9721158 | 0.97 | TDP1 (0.33) | TDP1PTGS1AKR1C3CYP2C9PARP1 | |
| Methacrylic Acid SCHEMBL8425146 | 0.97 | TDP1 (0.33) | TDP1PTGS1AKR1C3CYP2C9PARP1 | |
| SCHEMBL27734787 | 0.84 | PTGS1 (0.33) | PTGS1AKR1C3CYP2C9MAPTALDH1A1 | |
| Acrylic Acid SCHEMBL8426417 | 0.84 | LMNA (0.37) | TDP1ALDH1A1 | |
| Acrylic Acid SCHEMBL8426413 | 0.84 | LMNA (0.37) | TDP1ALDH1A1 | |
| SCHEMBL16653704 | 0.80 | CYP1A2 (0.38) | PTGS1AKR1C3CYP2C9PARP1PARP15 | |
| SCHEMBL1300006 | 0.80 | CYP1A2 (0.38) | PTGS1AKR1C3CYP2C9PARP1PARP15 | |
| SCHEMBL16653701 | 0.80 | CYP1A2 (0.38) | PTGS1AKR1C3CYP2C9PARP1PARP15 | |
| Methacrylic Acid SCHEMBL1443532 | 0.79 | HTT (0.39) | TDP1PTGS1AKR1C3CYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706759-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING ENTEROKINE-RELEASING SUBSTANCES IN MULTIPLE DOSAGE FORMS IN COMBINATION WITH GELLING AGENTS | Aphaia Pharma AG (CH) | 2026-03-11 | — | — | EP | claimed |
| WO-2025119939-A1 | TREATMENT OF OBESITY AND RELATED CONDITIONS BY CIRCADIAN ADMINISTRATION OF ENTEROKINE-STIMULATING COMPOSITIONS | APHAIA PHARMA AG (CH) | 2025-06-12 | — | — | WO | claimed |
| EP-4164592-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ENTEROKINE-RELEASING SUBSTANCES IN MULTIPLE DOSAGE FORMS IN COMBINATION WITH GELLING AGENTS | APHAIA IP AG (CH) | 2025-05-07 | — | — | EP | claimed |
| US-20240116037-A1 | SCRF COATINGS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2024-04-11 | — | — | US | claimed |
| WO-2024074802-A1 | SCRF COATINGS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2024-04-11 | — | — | WO | claimed |
| EP-4349458-A1 | SCRF COATINGS | Johnson Matthey Public Limited Company (GB) | 2024-04-10 | — | — | EP | claimed |
| US-20230233471-A1 | Pharmaceutical Compositions Containing Enterokine Releasing Substances In Multiple Dosage Forms In Combination With Gelling Agents | APHAIA PHARMA AG (CH) | 2023-07-27 | — | — | US | claimed |
| EP-3681922-B1 | RADIATION CURABLE AQUEOUS COMPOSITIONS | ALLNEX Belgium SA (BE) | 2022-12-07 | — | — | EP | claimed |
| US-20220331256-A1 | PHARMACEUTICAL ORAL DOSAGE FORMS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED DISEASES THROUGH ORCHESTRATED RELEASE OF ENTEROKINES | APHAIA PHARMA AG (CH) | 2022-10-20 | — | — | US | claimed |
| EP-3666262-B1 | PHARMACEUTICAL ORAL DOSAGE FORMS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED DISEASES THROUGH ORCHESTRATED RELEASE OF ENTEROKINES | APHAIA IP AG (CH) | 2021-11-10 | — | — | EP | claimed |
| WO-2020120518-A1 | PHARMACEUTICAL ORAL DOSAGE FORMS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED DISEASES THROUGH ORCHESTRATED RELEASE OF ENTEROKINES | APHAIA PHARMA AG (CH) | 2020-06-18 | — | — | WO | claimed |
| WO-2020120519-A1 | COMBINATORIAL ORAL TREATMENT OF METABOLIC DISORDERS THROUGH ORCHESTRATED RELEASE OF ENTEROKINES | APHAIA PHARMA AG (CH) | 2020-06-18 | — | — | WO | claimed |
| EP-3666262-A1 | PHARMACEUTICAL ORAL DOSAGE FORMS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED DISEASES THROUGH ORCHESTRATED RELEASE OF ENTEROKINES | Aphaia Pharma AG (CH) | 2020-06-17 | — | — | EP | claimed |
| CN-101381438-B | Compound material constructed by molecular engram and fluorescent conjugated polymer, preparation and application | TONGCHUANG HAICHENG SCIENCE TECHNOLOGY DEV BEIJING CO LTD | 2013-06-26 | — | — | CN | claimed |
| EP-1377369-B1 | SUBSTRATES, PREPARATION AND USE | CYTEC SURFACE SPECIALTIES SA (BE) | 2011-05-11 | — | — | EP | claimed |
| CN-101381438-A | Compound material constructed by molecular engram and fluorescent conjugated polymer, preparation and application | SHANGHAI INST MICROSYS & INF (CN) | 2009-03-11 | — | — | CN | claimed |
| EP-0747455-B1 | Friction coating for film backings | NORTON CO (US) | 1999-07-21 | — | — | EP | claimed |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-4267265-A | PLASTICIZER AND AN ORGANIC FLUORINE COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1981-05-12 | — | — | US | disclosed |
| US-4078004-A | OXIDATION OF ISOBUTYLENE, METAL OXIDE CATALYST, EXPANDED PERLITE SUPPORT | ROHM AND HAAS COMPANY (US) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | TDP1 2676/4885PTGS1 4700/4885AKR1C3 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.